Investigation of +405 and –460 Polymorphisms of Vascular Endothelial Growth Factor in Psoriasis and Short-Term Responsiveness to Efalizumab Therapy

Publisher： Karger

E-ISSN： 1421-9832|217|3|201-202

ISSN： 1018-8665

Source： Dermatology, Vol.217, Iss.3, 2008-06, pp. : 201-202

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Efficacy of Short-Term Cyclosporine Treatment to Control Psoriasis-Related Events during Efalizumab Therapy

By  

Dermatology, Vol. 218, Iss. 2, 2008-10 ,pp. : 146-150

Karger

Access to resources Recommend Favorite

A Short Cycle of Narrow-Band UVB Phototherapy in the Early Phase of Long-Term Efalizumab Can Provide a Quicker Remission of Moderate and Severe Psoriasis: A Pilot Study

By  

Dermatology, Vol. 218, Iss. 4, 2009-03 ,pp. : 321-326

Karger

Access to resources Recommend Favorite

Efficacy of Efalizumab in Psoriasis Patients Previously Treated with Tumour Necrosis Factor Blockers

By  

Dermatology, Vol. 219, Iss. 1, 2009-04 ,pp. : 48-53

Karger

Access to resources Recommend Favorite

Two Cases of Psoriasis Responding to Erlotinib: Time to Revisiting Inhibition of Epidermal Growth Factor Receptor in Psoriasis Therapy?

By  

Dermatology, Vol. 225, Iss. 2, 2012-10 ,pp. : 179-182

Karger

Access to resources Recommend Favorite

Vascular Endothelial Growth Factor Expression Induced by Proinflammatory Cytokines (Interleukin 1α, β) in Cells of the Human Pilosebaceous Unit

By  

Dermatology, Vol. 196, Iss. 1, 1998-03 ,pp. : 89-92

Karger

Access to resources Recommend Favorite